The
following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders
for the periods presented, because including them would have had an anti-dilutive effect:
SCHEDULE OF ANTI-DILUTIVE EFFECT
| | |
June 30, 2026 | | |
June 30, 2025 | |
| Restricted Stock options | |
| 16,923 | | |
| 36,195 | |
| Restricted Stock Units | |
| 99,680 | | |
| 168,603 | |
| Performance Stock units | |
| 50,658 | | |
| 50,658 | |
| Public warrants | |
| 486,413 | | |
| 486,413 | |
| Private warrants | |
| 556,666 | | |
| 556,666 | |
| Inducement warrants | |
| - | | |
| 958,400 | |
| Short term loan warrants | |
| 86,591 | | |
| 86,591 | |
| Private placement warrants | |
| 6,425 | | |
| 6,425 | |
| 2025 Convertible notes shares | |
| 698,989 | | |
| - | |
| 2025 Convertible notes warrants | |
| 411,245 | | |
| - | |
| Potentially dilutive shares | |
| 411,245 | | |
| - | |
| * |
The
Sponsor Earnout Shares (as defined in the Business Combination Agreement) were not included for purposes of calculating the number
of diluted shares outstanding as of June 30, 2026, as the Sponsor Earnout Shares remain contingently forfeitable, as the conditions
have not been met. |
|